نورميتن ٢٥ Israel - arabisk - Ministry of Health

نورميتن ٢٥

abic ltd. - atenolol 25 mg - tablets - beta blocking agents, selective - management of angina pectoris and hypertension, including hypertension of renal origin. late intervention after acute myocardial infarction.

أبيترن ٥٠ Israel - arabisk - Ministry of Health

أبيترن ٥٠

abic ltd. - diclofenac sodium 50 mg - suppositories - diclofenac - rheumatoid arthritis, osteoarthritis, low back pain and other acute musculoskeletal .disorders such as periarthritis, tendinitis, tenosynovitis, bursitis, sprains, strains and dislocation, ankylosing spondylitis and acute gout.control of pain and inflammation in orthopedic, dental, and other monor surgery.

ألفا D3 ٠.٢٥ مكغ كبسولات Israel - arabisk - Ministry of Health

ألفا d3 ٠.٢٥ مكغ كبسولات

teva pharmaceutical indust.ltd - alfacalcidol 0.25 mcg - capsules soft gelatin - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

ألفا D3 ١.٠ مكغ كبسولات Israel - arabisk - Ministry of Health

ألفا d3 ١.٠ مكغ كبسولات

teva pharmaceutical indust.ltd - alfacalcidol 1 mcg - capsules soft gelatin - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

تيڤعكوتان Israel - arabisk - Ministry of Health

تيڤعكوتان

teva pharmaceutical indust.ltd - clotrimazole 1 %; dexamethasone acetate 0.044 % - cream - dexamethasone - tevacutan is indicated for the treatment of mycotic infections of the skin complicated by inflammation and/or secondary infection.

بيكالوتاميد تيڤع ١٥٠ ملغ Israel - arabisk - Ministry of Health

بيكالوتاميد تيڤع ١٥٠ ملغ

teva pharmaceutical indust.ltd - bicalutamide 150 mg - tablets - bicalutamide - in patients with locally advanced prostate cancer (t3-t4 any n m0 t1-t2 n+ m0) bicalutamide is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

أكامولي للأطفال الكبار بطعم الفراولة Israel - arabisk - Ministry of Health

أكامولي للأطفال الكبار بطعم الفراولة

teva pharmaceutical indust.ltd - paracetamol 250 mg / 5 ml - syrup - paracetamol - analgesic, antipyretic.

بيكالوتاميد تيڤع ٥٠ ملغ Israel - arabisk - Ministry of Health

بيكالوتاميد تيڤع ٥٠ ملغ

teva pharmaceutical indust.ltd - bicalutamide 50 mg - tablets - bicalutamide - for the treatment of advanced prostate cancer in combination with lhrh analog therapy or surgical castration.

أناستروزول تيڤع Israel - arabisk - Ministry of Health

أناستروزول تيڤع

teva pharmaceutical indust.ltd - anastrozole 1 mg - tablets - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

ليتروزول تيڤع Israel - arabisk - Ministry of Health

ليتروزول تيڤع

teva pharmaceutical indust.ltd - letrozole 2.5 mg - tablets - letrozole - letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.